Form 8-K - Current report:
SEC Accession No. 0001104659-25-081160
Filing Date
2025-08-21
Accepted
2025-08-21 07:48:52
Documents
15
Period of Report
2025-08-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2524045d1_8k.htm   iXBRL 8-K 42742
2 EXHIBIT 10.1 tm2524045d1_ex10-1.htm EX-10.1 113732
3 EXHIBIT 99.1 tm2524045d1_ex99-1.htm EX-99.1 11217
7 GRAPHIC tm2524045d1_ex99-1img002.jpg GRAPHIC 10625
  Complete submission text file 0001104659-25-081160.txt   379260

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA nvax-20250820.xsd EX-101.SCH 3011
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE nvax-20250820_lab.xml EX-101.LAB 34239
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nvax-20250820_pre.xml EX-101.PRE 22356
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2524045d1_8k_htm.xml XML 3558
Mailing Address 700 QUINCE ORCHARD ROAD GAITHERSBURG MD 20878
Business Address 700 QUINCE ORCHARD ROAD GAITHERSBURG MD 20878 240-268-2000
NOVAVAX INC (Filer) CIK: 0001000694 (see all company filings)

EIN.: 222816046 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-26770 | Film No.: 251238396
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)